George Giotopoulos

Wellcome/MRC Cambridge Stem Cell Institute — United Kingdom

Medicine · Health Sciences

24h-index3.7kcitations74works4.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(43), Protein Degradation and Inhibitors(24), Genomics and Chromatin Dynamics(12), Epigenetics and DNA Methylation(12), Histone Deacetylase Inhibitors Research(11)

Publications74 total

2024 – A STEP-WISE AND DETERMINISTIC LEUKEMIA MOUSE MODEL REMINISCENT OF JMML WITH ENDOGENOUS ACQUISITION OF PATIENT-RELEVANT RTK–RAS MUTATIONS
Experimental Hematology·2025
Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML.
Apollo (University of Cambridge)·2025Open Access
A Step-wise, Deterministic and Fatal Mouse Model of Myeloid Neoplasm with Spontaneous Acquisition of Patient-relevant RTK–RAS Mutations
2025Open Access
Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in <i>NPM1</i>-mutant AML
Blood·2025· 1 citedOpen Access
CREBBP inactivation sensitizes B cell acute lymphoblastic leukemia to ferroptotic cell death upon BCL2 inhibition
Nature Communications·2025· 5 citedOpen Access
Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding protein
Nature Biotechnology·2025· 16 citedOpen Access
Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis
Nature·2025· 25 citedOpen Access
Delayed Trp53 activation protects Dnmt3a-mutant hematopoietic stem cells from inflammatory attrition.
2025
A Step-Wise, Deterministic and Fatal Mouse Model of Myeloid Neoplasm with Spontaneous Acquisition of Patient-Relevant RTK–RAS Mutations
SSRN Electronic Journal·2025Open Access
Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation
Blood·2024· 12 citedOpen Access
Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation
Blood·2024Open Access
Delayed Trp53 Activation Protects <i>Dnmt3a</i>-Mutant Haematopoietic Stem Cells from Inflammatory Attrition
Blood·2024Open Access
Abstract 363: Genetic or pharmacological inactivation of CREBBP sensitizes B-cell acute lymphoblastic leukemia to ferroptotic cell death upon BCL2 inhibition
Cancer Research·2024
Preleukemic single-cell landscapes reveal mutation-specific mechanisms and gene programs predictive of AML patient outcomes
Cell Genomics·2023· 12 citedOpen Access
Genetic or pharmacological inactivation of CREBBP sensitizes B-cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 Inhibition
2023Open Access
In vivo screening characterizes chromatin factor functions during normal and malignant hematopoiesis
Nature Genetics·2023· 48 citedOpen Access
Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death
Nature Communications·2023· 22 citedOpen Access
HOXA9 forms a repressive complex with nuclear matrix–associated protein SAFB to maintain acute myeloid leukemia
Blood·2022· 13 citedOpen Access
HOXA9 Nucleates a Repressive Chromatin Complex with Nuclear Matrix-Associated Protein- Safb to Maintain Acute Myeloid Leukemia
Blood·2022
HOXA9 forms a repressive complex with nuclear matrix-associated protein SAFB to maintain acute myeloid leukemia
2022· 1 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Brian J.P. Huntly(43), George S. Vassiliou(18), Paolo Gallipoli(16), Sarah J. Horton(15), Haiyang Yun(11), Daniel Sasca(11), Ryan Asby(10), Malgorzata Gozdecka(9), Eshwar Meduri(8), Faisal Basheer(8), Ludovica Marando(8), Rab K. Prinjha(7), Konstantinos Tzelepis(7), Shuchi Agrawal‐Singh(7), Shabana Vohra(6), Berthold Göttgens(6), David J. Adams(6), Justyna Rak(6), Mark A. Dawson(5), Wai-In Chan(5)